查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1772192

日本基因組編輯市場規模、佔有率、趨勢分析報告：按技術、交付方式、應用、最終用途、模式和細分市場預測，2025 年至 2033 年

Japan Genome Editing Market Size, Share & Trends Analysis Report By Technology, By Delivery Method, By Application, By Mode, By End Use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10個工作天內

價格

日本基因組編輯市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，日本基因組編輯市場預計到2033年將達到14.5億美元，2025年至2033年期間的複合年成長率為17.97%。

日本基因組編輯市場正經歷強勁擴張，這得益於精準醫療、再生醫學和農業生物技術投資的不斷增加。對下一代療法（尤其是基因治療、罕見疾病治療和個人化腫瘤治療方案）的日益關注，推動了對 CRISPR-Cas9、TALEN 和鹼基編輯等先進基因組編輯技術的需求。監管激勵措施和政府支援措施（例如資助生物技術創新和簡化臨床核准流程）進一步推動了市場發展勢頭。

強大的學術和研究基礎設施以及全球知名研究機構的存在，為創新和跨部門合作提供了支持。製藥公司、生技新興企業和教育聯盟正日益加強合作，致力於將基因編輯領域的突破轉化為可行的臨床和商業應用。日本人口老化和慢性遺傳病患疾病率的上升，迫切需要針對基因組的干涉措施，從而推動了對安全、有效且可擴展的基因編輯平台的需求。

遞送系統、精準標靶和降低脫靶風險的技術進步正在拓展基因組編輯的治療應用。與數位工具和人工智慧主導的生物資訊平台的整合正在改善標靶發現，最佳化設計工作流程，並加速臨床前開發。在農業和食品生物技術領域，基因編輯正被用於開發抗病產量作物，以滿足國家糧食安全和永續性目標。

憑藉跨部門夥伴關係、活性化的研發活動以及扶持性政策框架，日本的基因組編輯市場有望在塑造精準生物技術的未來方面發揮主導作用。策略聯盟、在地化生產以及不斷成長的智慧財產權組合正在鞏固日本作為治療和非治療應用領域基因組編輯創新關鍵樞紐的地位。

日本基因組編輯市場報告重點

  • 從技術面來看，CRISPR/Cas9 將主導日本基因組編輯市場，2024 年的市場佔有率將達到 44.14%。這項優勢歸功於 CRISPR/Cas9 在標靶基因組修飾方面的卓越效率、精準度和成本效益。 CRISPR/Cas9 在研究機構、生物技術新興企業和製藥公司中的廣泛應用，反映了其加速功能基因組學研究、治療方法開發和農業創新的能力。 CRISPR/Cas9 工具相對易於設計且擴充性，適用於體外和體內應用。
  • 依遞送方式分類，體內基因組編輯將在2024年佔據50.63%的市場佔有率，引領市場。這得益於基因治療和再生醫學領域投資的不斷成長，尤其是在遺傳疾病和癌症治療領域。日本先進的醫療基礎設施和對治癒性療法的重視，推動了脂質奈米顆粒和腺結合病毒載體 (AAV) 等新型遞送平台的開發，從而實現了更高效的體內基因轉移。直接在患者體內編輯基因的能力具有變革性的潛力，並持續吸引臨床試驗活動和投資。
  • 從應用角度來看，基因工程將在2024年創造最高收入，市場佔有率達73.16%。該領域的成長得益於日本在疾病建模、治療方法探索和功能基因組學研究方面的努力。基因工程在學術界和產業界被廣泛用於開發客製化細胞株、建構模型生物以及推進基因治療研發管線。基因工程在農業和水產養殖的精準育種中也扮演關鍵角色。
  • 在生技新興企業和研究機構中，外包基因組編輯服務正變得越來越普遍。合約服務提供者可以提供專業知識、基礎設施和監管支持，幫助創新者加快產品上市速度並控制開發成本。日本強大的合約研究和製造組織生態系統為臨床前、臨床和商業化階段的基因編輯提供支援。
  • 從最終用途來看，生技和製藥公司將主導日本基因組編輯市場，到2024年將佔49.66%的佔有率。這些公司正在利用基因組編輯加速藥物研發，開發基因和細胞療法，並探索複雜疾病的新治療方法。強大的研發開發平臺和不斷增加的政府獎勵使這些最終用戶處於創新的前沿。與學術機構和全球生物技術公司的合作進一步鞏固了他們的地位，使其成為基因組編輯技術商業性應用的核心參與者。
  • 2025 年 1 月，Takara Bio USA Holdings 完成對加州 Curio Biosciences 公司的收購，將該公司的 Trekker 和 Seeker 空間生物學平台整合到美國單細胞體學產品組合中。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章市場變數、趨勢和範圍

  • 市場展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 日本基因組編輯市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19影響分析

第4章日本基因組編輯市場：技術商業分析

  • 技術細分儀表板
  • 日本基因組編輯市場技術變遷分析
  • 日本基因組編輯市場規模及趨勢分析（分技術，2021-2033）
  • CRISPR/Cas9
  • TALEN/MegaTAL
  • ZFN
  • Meganucleases
  • 其他

第5章日本基因組編輯市場：交付方式的商業分析

  • 配送方式細分儀表板
  • 日本基因組編輯市場交付方式的波動分析
  • 日本基因組編輯市場規模及趨勢分析（以交付方式，2021-2033）
  • 體外
  • 體內

第6章日本基因組編輯市場：應用業務分析

  • 應用程式細分儀表板
  • 日本基因組編輯市場應用變化分析
  • 日本基因組編輯市場規模及趨勢分析（依應用，2021-2033）
  • 基因工程
  • 臨床應用

第7章日本基因組編輯市場：模式商業分析

  • 模式細分儀表板
  • 日本基因組編輯市場的波動
  • 日本基因組編輯市場規模及趨勢分析（按模式，2021-2033）
  • 合約
  • 內部

第8章日本基因組編輯市場：最終用途估計與趨勢分析

  • 最終用途細分儀表板
  • 日本基因組編輯市場最終用途趨勢分析
  • 日本基因組編輯市場規模與趨勢分析（依最終用途，2021-2033 年）
  • 生物技術和製藥公司
  • 學術研究所
  • 合約研究組織

第9章 競爭態勢

  • 公司/競爭對手分類
  • 戰略地圖
  • 2024年企業市場分析
  • 公司簡介/上市公司
    • Merck KGaA
    • Takara Bio Inc.
    • Revvity, Inc.
    • Danaher Corporation
    • GenScript
    • New England Biolabs
    • Lonza
    • Thermo Fisher Scientific, Inc.
    • Charles River Laboratories
    • Eurofins Scientific
Product Code: GVR-4-68040-648-1

Japan Genome Editing Market Growth & Trends:

The Japan genome editing market size is projected to reach USD 1.45 billion by 2033, growing at a CAGR of 17.97% from 2025 to 2033, according to a new report by Grand View Research, Inc. The Japan genome editing market is witnessing robust expansion, propelled by increasing investment in precision medicine, regenerative therapies, and agricultural biotechnology. The growing focus on next-generation therapeutics, particularly gene therapies, rare disease treatments, and personalized oncology solutions, fuels demand for advanced genome editing technologies such as CRISPR-Cas9, TALENs, and base editors. Regulatory encouragement and supportive government initiatives, including funding for biotech innovation and streamlining of clinical approval processes, further accelerate market momentum.

A strong academic and research infrastructure and the presence of globally recognized institutions underpin innovation and collaboration across sectors. Pharmaceutical companies, biotech startups, and educational consortia are increasingly converging to translate gene editing breakthroughs into viable clinical and commercial applications. Japan's aging population and rising incidence of chronic genetic disorders are also driving urgency around genome-targeted interventions, catalyzing demand for safe, effective, and scalable editing platforms.

Technological advancements in delivery systems, precision targeting, and off-target risk mitigation are expanding genome editing's therapeutic applicability. Integration with digital tools and AI-driven bioinformatics platforms is improving target discovery, optimizing design workflows, and accelerating preclinical development. In agriculture and food biotechnology, gene editing is applied to develop disease-resistant, high-yield crops, aligning with national food security and sustainability goals.

With cross-sector partnerships, increased R&D activity, and supportive policy frameworks, the Japan genome editing market is well-positioned to play a leading role in shaping the future of precision biotechnology. Strategic alliances, localized manufacturing, and a growing IP portfolio reinforce Japan's position as a key hub for genome editing innovation in therapeutic and non-therapeutic applications.

Japan Genome Editing Market Report Highlights:

  • By technology, CRISPR/Cas9 dominated the Japan genome editing market with a market share of 44.14% in 2024. This dominance stems from CRISPR/Cas9's superior efficiency, precision, and cost-effectiveness in targeted genome modifications. Its widespread adoption across research institutes, biotech startups, and pharmaceutical companies reflects its ability to accelerate functional genomics studies, therapeutic development, and agricultural innovation. The relatively easier design and scalability of CRISPR/Cas9 tools make them the preferred choice for both in vitro and in vivo applications.
  • By delivery method, in vivo genome editing led the market with a market share of 50.63% in 2024, driven by rising investments in gene therapy and regenerative medicine, especially for treating inherited diseases and cancers. Japan's advanced healthcare infrastructure and focus on curative therapies have fueled the development of novel delivery platforms, such as lipid nanoparticles and adeno-associated viral vectors (AAVs), enabling more effective gene transfer in living organisms. The ability to directly edit genes within the patient offers transformative potential and continues to attract clinical trial activity and investment.
  • By application, genetic engineering emerged as the leading segment, with a market share of 73.16% in 2024, contributing the highest revenue share. The segment's growth is driven by Japan's commitment to disease modeling, therapeutic discovery, and functional genomics research. Genetic engineering is widely used across academia and industry to develop customized cell lines, engineer model organisms, and advance gene therapy pipelines. It also plays a crucial role in precision breeding for agriculture and aquaculture, which are strategic sectors in Japan's biotech innovation agenda.
  • By mode, the contract segment held the largest share of 66.77% in 2024, as outsourcing genome editing services becomes increasingly common among biotech startups and research institutions. Contract service providers offer specialized expertise, infrastructure, and regulatory support, allowing innovators to reduce time-to-market and control development costs. Japan's strong contract research and manufacturing organization ecosystem supports gene editing across preclinical, clinical, and commercial phases.
  • By end use, biotechnology and pharmaceutical companies dominated the Japan genome editing market with a share of 49.66% in 2024. These companies leverage genome editing to accelerate drug discovery, develop gene and cell therapies, and explore novel treatment modalities for complex diseases. With robust R&D pipelines and increasing government incentives, these end users are at the forefront of innovation. Collaborations with academic institutions and global biotech firms further strengthen their position, making them central players in the commercial Application of genome editing technologies.
  • In January 2025, Takara?Bio USA Holdings, Inc. completed the acquisition of California?based Curio Bioscience, integrating its Trekker and Seeker spatial?biology platforms into its U.S. single?cell omics portfolio.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Technology Segment
    • 1.2.2. Method Segment
    • 1.2.3. Application Segment
    • 1.2.4. Mode Segment
    • 1.2.5. End-use Segment
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Japan Genome Editing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Japan Genome Editing Market: Technology Business Analysis

  • 4.1. Technology Segment Dashboard
  • 4.2. Japan Genome Editing Market Technology Movement Analysis
  • 4.3. Japan Genome Editing Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
  • 4.4. CRISPR/Cas9
    • 4.4.1. CRISPR/Cas9 market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.5. TALENs/MegaTALs
    • 4.5.1. TALENS/MegaTALs market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6. ZFN
    • 4.6.1. ZFN market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.7. Meganucleases
    • 4.7.1. Meganucleases market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Japan Genome Editing Market: Delivery Method Business Analysis

  • 5.1. Delivery Method Segment Dashboard
  • 5.2. Japan Genome Editing Market Delivery Method Movement Analysis
  • 5.3. Japan Genome Editing Market Size & Trend Analysis, by Delivery Method, 2021 to 2033 (USD Million)
  • 5.4. Ex-vivo
    • 5.4.1. Ex-vivo market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.5. In- vivo
    • 5.5.1. In-Vivo market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Japan Genome Editing Market: Application Business Analysis

  • 6.1. Application Segment Dashboard
  • 6.2. Japan Genome Editing Market Application Movement Analysis
  • 6.3. Japan Genome Editing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 6.4. Genetic Engineering
    • 6.4.1. Genetic Engineering market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.2. Cell line engineering
      • 6.4.2.1. Cell line engineering market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.3. Animal genetic engineering
      • 6.4.3.1. Animal genetic engineering market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.4. Plant genetic engineering
      • 6.4.4.1. Plant genetic engineering market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.5. Others
      • 6.4.5.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Clinical Applications
    • 6.5.1. Clinical Applications market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.2. Therapy Development
      • 6.5.2.1. Therapy Development market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.3. Diagnostics Development
      • 6.5.3.1. Diagnostics Development market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Japan Genome Editing Market: Mode Business Analysis

  • 7.1. Mode Segment Dashboard
  • 7.2. Japan Genome Editing Market Mode Movement Analysis
  • 7.3. Japan Genome Editing Market Size & Trend Analysis, by Mode, 2021 to 2033 (USD Million)
  • 7.4. Contract
    • 7.4.1. Contract market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5. In- house
    • 7.5.1. In-house market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Japan Genome Editing Market: End Use Estimates & Trend Analysis

  • 8.1. End Use Segment Dashboard
  • 8.2. Japan Genome Editing Market End Use Movement Analysis
  • 8.3. Japan Genome Editing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 8.4. Biotechnology & Pharmaceutical Companies
    • 8.4.1. Biotechnology & pharmaceutical companies market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5. Academic & Research Institutes
    • 8.5.1. Academic & research institutes market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Contract Research Organizations
    • 8.6.1. Contract research organizations market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2024
  • 9.4. Company Profiles/Listing
    • 9.4.1. Merck KGaA
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Takara Bio Inc.
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Revvity, Inc.
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Danaher Corporation
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. GenScript
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. New England Biolabs
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Lonza
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Thermo Fisher Scientific, Inc.
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Charles River Laboratories
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. Eurofins Scientific
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Japan Genome editing Market, By technology, 2021 - 2033 (USD Million)
  • Table 5 Japan Genome editing Market, By delivery method, 2021 - 2033 (USD Million)
  • Table 6 Japan Genome editing Market, By application, 2021 - 2033 (USD Million)
  • Table 7 Japan Genome editing Market, By mode, 2021 - 2033 (USD Million)
  • Table 8 Japan Genome editing Market, By end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Japan genome editing market segmentation
  • Fig. 2 Information procurement
  • Fig. 3 Data analysis models
  • Fig. 4 Market formulation and validation
  • Fig. 5 Data validating & publishing
  • Fig. 6 Market research process
  • Fig. 7 Information procurement
  • Fig. 8 Primary research
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Japan genome editing market: Technology outlook key takeaways
  • Fig. 13 Japan genome editing market: Technology movement analysis
  • Fig. 14 Japan CRISPR/Cas9 market, 2021 - 2033 (USD Million)
  • Fig. 15 Japan TALENs/MegaTALs market, 2021 - 2033 (USD Million)
  • Fig. 16 Japan ZFN market, 2021 - 2033 (USD Million)
  • Fig. 17 Japan meganucleases market, 2021 - 2033 (USD Million)
  • Fig. 18 Japan others market, 2021 - 2033 (USD Million)
  • Fig. 19 Japan genome editing market: Delivery Method outlook and key takeaways
  • Fig. 20 Japan genome editing market: Delivery Method movement analysis
  • Fig. 21 Japan ex- vivo market, 2021 - 2033 (USD Million)
  • Fig. 22 Japan in- vivo market, 2021 - 2033 (USD Million)
  • Fig. 23 Japan genome editing market: Application outlook and key takeaways
  • Fig. 24 Japan genome editing market: Application movement analysis
  • Fig. 25 Japan genetic engineering market, 2021 - 2033 (USD Million)
  • Fig. 26 Japan cell line engineering market, 2021 - 2033 (USD Million)
  • Fig. 27 Japan animal engineering market, 2021 - 2033 (USD Million)
  • Fig. 28 Japan plant engineering market, 2021 - 2033 (USD Million)
  • Fig. 29 Japan others market, 2021 - 2033 (USD Million)
  • Fig. 30 Japan clinical applications market, 2021 - 2033 (USD Million)
  • Fig. 31 Japan diagnostics development market, 2021 - 2033 (USD Million)
  • Fig. 32 Japan therapy development market, 2021 - 2033 (USD Million)
  • Fig. 33 Japan genome editing market: Mode outlook and key takeaways
  • Fig. 34 Japan genome editing market: Mode movement analysis
  • Fig. 35 Japan contract market, 2021 - 2033 (USD Million)
  • Fig. 36 Japan in- house market, 2021 - 2033 (USD Million)
  • Fig. 37 Japan genome editing market: End use outlook and key takeaways
  • Fig. 38 Japan genome editing market: End use movement analysis
  • Fig. 39 Japan biotechnology & pharmaceutical companies market, 2021 - 2033 (USD Million)
  • Fig. 40 Japan academic & research institutes market, 2021 - 2033 (USD Million)
  • Fig. 41 Japan contract research organizations market, 2021 - 2033 (USD Million)